Ayushakti B.v.

Ayushakti B.V. is a Netherlands-based pharmaceutical importer specializing in Ayurvedic and herbal products. Established in 2002, the company is headquartered at Harregatplein 5J, 3214VP, Zuidland, Netherlands. It operates as a corporation with a share capital of €24,000. Ayushakti B.V. is part of a larger group, with its global ultimate parent company being Ayushakti Ayurved Private Limited, located in Mumbai, India. The company plays a significant role in the Netherlands' pharmaceutical distribution network, focusing on the import and distribution of Ayurvedic formulations.

Ayushakti B.V. operates from its headquarters in Zuidland, Netherlands. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's import activities suggest a well-established distribution network within the Netherlands. The geographic coverage primarily includes the Dutch market, with potential distribution to other European countries, though specific details are not available.

In the Netherlands' pharmaceutical supply chain, Ayushakti B.V. functions as a primary wholesaler and distributor of Ayurvedic and herbal products. The company's focus on importing finished pharmaceutical formulations from India indicates its role in sourcing and supplying these specialized products to the Dutch market. Ayushakti B.V. is not identified as a parallel importer, hospital supplier, or logistics intermediary based on available data.

Ayushakti B.V. demonstrates a high level of supplier concentration, sourcing 100% of its imported pharmaceutical formulations from a single supplier: Ayushakti Ayurved Private Limited. This single-source dependency suggests a strategic choice to maintain consistency and quality in product offerings. The stability of this relationship is evidenced by the substantial volume of imports, with 140 shipments valued at $513,000 USD over the period from 2022 to 2026. The consistent sourcing pattern indicates a stable and ongoing partnership between Ayushakti B.V. and its Indian supplier.

The resilience of Ayushakti B.V.'s supply chain is closely tied to its exclusive relationship with Ayushakti Ayurved Private Limited. The lack of backup suppliers may pose a risk in the event of supply disruptions. However, the company's focus on a single supplier allows for streamlined operations and quality control. The diversity of formulations imported, with 131 unique formulations, suggests a broad product range, potentially mitigating risks associated with product shortages. Specific details regarding shipping route exposure and the regulatory compliance of the key supplier are not publicly available.

Ayushakti B.V.'s sourcing pattern, characterized by a single-source dependency, positions the company to leverage deep relationships and consistent product quality. This strategy may enhance its competitive position in the niche market of Ayurvedic and herbal products in the Netherlands. For Indian exporters seeking to become alternative suppliers, the lack of diversification in Ayushakti B.V.'s sourcing presents an opportunity to introduce complementary products or to offer competitive advantages in terms of pricing, quality, or innovation.

In the Netherlands, the Medicines Evaluation Board (MEB) is the primary regulatory authority overseeing the authorization and supervision of medicinal products. The key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics, the marketing authorization pathway involves obtaining a parallel import marketing authorization from the MEB, provided the product is already authorized in another EU member state. (english.cbg-meb.nl)

Importers of medicinal products in the Netherlands must obtain a pharmaceutical permit from the Dutch Ministry of Health, Welfare, and Sport (VWS). This permit is mandatory for companies involved in the wholesale or packaging of medicines. (business.gov.nl) Regarding Good Manufacturing Practice (GMP) certification, the Netherlands recognizes EU GMP, WHO GMP, and PIC/S standards. Importers must ensure that their suppliers hold valid GMP certificates from recognized authorities to comply with Dutch regulations.

Imported medicinal products must undergo batch testing to ensure quality and safety. Stability requirements are set to guarantee the product's efficacy throughout its shelf life. Labeling must be in Dutch and include essential information such as dosage instructions, side effects, and storage conditions. Serialization mandates may apply to facilitate traceability and prevent counterfeit products, aligning with EU regulations.

Between 2024 and 2026, the Netherlands implemented the Carbon Border Adjustment Mechanism (CBAM) Regulation, affecting imports of carbon-intensive products. This regulation requires importers to obtain authorization, submit CBAM declarations, and pay for the CO₂ emissions associated with the production of imported goods. While primarily targeting products like iron, steel, and cement, Ayushakti B.V. should assess the impact of this regulation on its import operations. (business.gov.nl)

Ayushakti B.V. focuses on importing Ayurvedic and herbal products, including formulations such as tablets, capsules, syrups, and injections. The market demand for these products in the Netherlands is driven by a growing consumer interest in natural and alternative medicine. The company's strategic emphasis on these therapeutic areas aligns with global health trends favoring holistic and plant-based treatments.

Ayushakti B.V. employs a sourcing strategy centered on importing generic Ayurvedic formulations from India. The company's exclusive relationship with Ayushakti Ayurved Private Limited indicates a preference for established suppliers with a proven track record in quality and compliance. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable fit for Ayushakti B.V.'s procurement needs.

Based on its product mix, Ayushakti B.V. serves the niche segment of the Netherlands market focused on Ayurvedic and herbal products. The company's offerings are likely distributed through retail pharmacies, health food stores, and online platforms catering to consumers seeking natural health solutions. While not identified as a hospital supplier or government tender participant, Ayushakti B.V.'s products may also be available in specialized clinics and wellness centers.

There is a realistic opportunity for new Indian suppliers to enter Ayushakti B.V.'s supply chain, especially if they can offer complementary products or innovations that align with the company's focus on Ayurvedic and herbal formulations. Gaps in Ayushakti B.V.'s current sourcing may include specific product categories or formulations not currently offered. Indian exporters can explore these areas to establish partnerships and expand their market presence in the Netherlands.

Indian exporters aiming to supply Ayushakti B.V. and the Netherlands market must ensure their products comply with EU and Dutch regulations. This includes obtaining necessary marketing authorizations, adhering to GMP standards recognized by the EU, and ensuring product labeling meets Dutch language requirements. Additionally, exporters should be prepared to provide documentation for batch testing, stability studies, and serialization as mandated by Dutch authorities.

To build a relationship with Ayushakti B.V., Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with EU and Dutch regulations. Participating in relevant trade fairs and industry events in the Netherlands can also facilitate introductions. A clear regulatory filing strategy, including obtaining necessary authorizations and certifications, is essential. Timelines for regulatory approvals can vary; therefore, exporters should plan accordingly to meet Ayushakti B.V.'s procurement schedules.